Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial.
Reimer T, Stachs A, Veselinovic K, Kühn T, Heil J, Polata S, Marmé F, Müller T, Hildebrandt G, Krug D, Ataseven B, Reitsamer R, Ruth S, Denkert C, Bekes I, Zahm DM, Thill M, Golatta M, Holtschmidt J, Knauer M, Nekljudova V, Loibl S, Gerber B. Reimer T, et al. Among authors: zahm dm. N Engl J Med. 2024 Dec 12. doi: 10.1056/NEJMoa2412063. Online ahead of print. N Engl J Med. 2024. PMID: 39665649
Patient-reported outcomes for the Intergroup Sentinel Mamma study (INSEMA): A randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer.
Reimer T, Stachs A, Veselinovic K, Polata S, Müller T, Kühn T, Heil J, Ataseven B, Reitsamer R, Hildebrandt G, Knauer M, Golatta M, Stefek A, Zahm DM, Thill M, Nekljudova V, Krug D, Loibl S, Gerber B; INSEMA investigators. Reimer T, et al. Among authors: zahm dm. EClinicalMedicine. 2022 Nov 25;55:101756. doi: 10.1016/j.eclinm.2022.101756. eCollection 2023 Jan. EClinicalMedicine. 2022. PMID: 36457648 Free PMC article.
Deep learning to predict breast cancer sentinel lymph node status on INSEMA histological images.
Marmé F, Krieghoff-Henning E, Gerber B, Schmitt M, Zahm DM, Bauerschlag D, Forstbauer H, Hildebrandt G, Ataseven B, Brodkorb T, Denkert C, Stachs A, Krug D, Heil J, Golatta M, Kühn T, Nekljudova V, Gaiser T, Schönmehl R, Brochhausen C, Loibl S, Reimer T, Brinker TJ. Marmé F, et al. Among authors: zahm dm. Eur J Cancer. 2023 Dec;195:113390. doi: 10.1016/j.ejca.2023.113390. Epub 2023 Oct 18. Eur J Cancer. 2023. PMID: 37890350 Free article.
Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men: Results from the MALE Phase 2 Randomized Clinical Trial.
Reinisch M, Seiler S, Hauzenberger T, Kamischke A, Schmatloch S, Strittmatter HJ, Zahm DM, Thode C, Furlanetto J, Strik D, Möbus V, Reimer T, Sinn BV, Stickeler E, Marmé F, Janni W, Schmidt M, Rudlowski C, Untch M, Nekljudova V, Loibl S. Reinisch M, et al. Among authors: zahm dm. JAMA Oncol. 2021 Apr 1;7(4):565-572. doi: 10.1001/jamaoncol.2020.7442. JAMA Oncol. 2021. PMID: 33538790 Free PMC article. Clinical Trial.
MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial.
Jank P, Gehlhaar C, Bianca L, Caterina F, Andreas S, Karn T, Marmé F, Sinn HP, van Mackelenbergh M, Sinn B, Zahm DM, Ingold-Heppner B, Schem C, Stickeler E, Fasching PA, Nekljudova V, Taube ET, Heppner F, Müller V, Denkert C, Loibl S. Jank P, et al. Among authors: zahm dm. PLoS One. 2020 Aug 25;15(8):e0238021. doi: 10.1371/journal.pone.0238021. eCollection 2020. PLoS One. 2020. PMID: 32841306 Free PMC article.
Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA).
Decker T, Lüdtke-Heckenkamp K, Melnichuk L, Hirmas N, Lübbe K, Zahn MO, Schmidt M, Denkert C, Lorenz R, Müller V, Zahm DM, Mundhenke C, Bauer S, Thill M, Seropian P, Filmann N, Loibl S. Decker T, et al. Among authors: zahm dm. Breast. 2023 Dec;72:103575. doi: 10.1016/j.breast.2023.08.007. Epub 2023 Sep 1. Breast. 2023. PMID: 37690320 Free PMC article. Clinical Trial.
Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer.
Denkert C, Schneeweiss A, Rey J, Karn T, Hattesohl A, Weber KE, Rachakonda S, Braun M, Huober J, Jank P, Sinn HP, Zahm DM, Felder B, Hanusch C, Teply-Szymanski J, Marmé F, Fehm T, Thomalla J, Sinn BV, Stiewe T, Marczyk M, Blohmer JU, van Mackelenbergh M, Schem C, Staib P, Link T, Müller V, Stickeler E, Stover DG, Solbach C, Metzger-Filho O, Jackisch C, Geyer CE Jr, Fasching PA, Pusztai L, Nekljudova V, Untch M, Loibl S. Denkert C, et al. Among authors: zahm dm. Cell Rep Med. 2024 Nov 19;5(11):101825. doi: 10.1016/j.xcrm.2024.101825. Cell Rep Med. 2024. PMID: 39566464 Free PMC article. Clinical Trial.
Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy.
Furlanetto J, Möbus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU, Lübbe K, Untch M, Salat C, Huober J, Klare P, Schmutzler R, Couch FJ, Lederer B, Gerber B, Zahm DM, Bauerfeind I, Nekljudova V, Hanusch C, Jackisch C, Link T, Hahnen E, Loibl S, Fasching PA. Furlanetto J, et al. Among authors: zahm dm. Eur J Cancer. 2021 Mar;145:44-52. doi: 10.1016/j.ejca.2020.12.007. Epub 2021 Jan 7. Eur J Cancer. 2021. PMID: 33423006
Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer.
Sinn BV, Loibl S, Hanusch CA, Zahm DM, Sinn HP, Untch M, Weber K, Karn T, Becker C, Marmé F, Schmitt WD, Müller V, Schem C, Treue D, Stickeler E, Klauschen F, Burchardi N, Furlanetto J, van Mackelenbergh M, Fasching PA, Schneeweiss A, Denkert C. Sinn BV, et al. Among authors: zahm dm. Clin Cancer Res. 2021 May 1;27(9):2584-2591. doi: 10.1158/1078-0432.CCR-20-3113. Epub 2021 Feb 16. Clin Cancer Res. 2021. PMID: 33593886
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
Meyer-Wilmes P, Huober J, Untch M, Blohmer JU, Janni W, Denkert C, Klare P, Link T, Rhiem K, Bayer C, Reinisch M, Bjelic-Radisic V, Zahm DM, Hanusch C, Solbach C, Heinrich G, Hartkopf AD, Schneeweiss A, Fasching P, Filmann N, Nekljudova V, Holtschmidt J, Stickeler E, Loibl S. Meyer-Wilmes P, et al. Among authors: zahm dm. ESMO Open. 2024 May;9(5):103009. doi: 10.1016/j.esmoop.2024.103009. Epub 2024 Apr 24. ESMO Open. 2024. PMID: 38663168 Free PMC article. Clinical Trial.
40 results